US · SNGX
Soligenix, Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Princeton, NJ 08540
- Website
- soligenix.com
Price · as of 2024-12-31
$0.35
Market cap 11.9M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | — | — |
| Intrinsic Value(DCF) | — | — |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | $8,640.00 | $3,548.60 | $0.00 | $0.00 | $2,335.45 |
| 2011 | $1,440.00 | $11,438.20 | $44,655.59 | $0.00 | $0.00 |
| 2012 | $3,792.00 | $2,186.37 | $0.00 | $0.00 | $2,708.59 |
| 2013 | $4,992.00 | $17,455.22 | $0.00 | $0.00 | $0.00 |
| 2014 | $4,464.00 | $54,885.47 | $95,434.41 | $0.00 | $0.00 |
| 2015 | $2,040.00 | $4,731.76 | $646,211.55 | $0.00 | $0.00 |
| 2016 | $626.40 | $6,048.38 | $495,746.86 | $0.00 | $0.00 |
| 2017 | $489.60 | $2,142.15 | $0.00 | $0.00 | $10,547.73 |
| 2018 | $223.20 | $171.65 | $0.00 | $0.00 | $0.00 |
| 2019 | $717.60 | $287.04 | $0.00 | $0.00 | $3,336.34 |
| 2020 | $429.60 | $537.71 | $0.00 | $0.00 | $4,653.52 |
| 2021 | $172.80 | $82.48 | $0.00 | $0.00 | $5,795.97 |
| 2022 | $51.36 | $43.48 | $0.00 | $0.00 | $0.00 |
| 2023 | $12.32 | $715.37 | |||
| 2024 | $2.37 |
AI valuation
Our deep-learning model estimates Soligenix, Inc.'s (SNGX) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- —
- Current price
- $0.35
- AI upside
- —
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
—
— upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| SNGX | Soligenix, Inc. | $0.35 | 11.9M | — | — | — | — | -0.48 | 0.96 | — | 0.25 | — | 0.96 | 0.00% | — | — | -248.97% | 387.20% | -88.11% | 0.36 | — | 1.82 | 1.61 | 0.67 | -6066.00% | — | -233.00% | -213.60% | -1.73 | 361.77% | 0.00% | 0.00% | 35.16% | 0.25 | 0.29 | — | -38.99 |
| CMND | Clearmind Medicine Inc. | $1.13 | 154.43K | — | — | — | — | -0.08 | 0.25 | — | 0.94 | — | 0.27 | 0.00% | — | — | -180.28% | 180.16% | -58.05% | 1.49 | -290.07 | 1.22 | 1.21 | 0.58 | -5494.00% | — | -189.00% | -1590.11% | -0.97 | 150.51% | 0.00% | 0.00% | 0.00% | 0.62 | 0.74 | — | -9.25 |
| ENSC | Ensysce Biosciences, Inc. | $0.62 | 1.48M | +2,572,138,798% | +223% | — | — | -1.10 | 2.36 | 1.68 | -0.83 | — | 2.36 | -38.57% | -129.17% | -153.30% | -471.83% | 16069.72% | -192.33% | 0.08 | -5.22 | 2.42 | 1.64 | 0.48 | -256.00% | 13353.00% | 6959834645.00% | -85550186.53% | -3399198.17 | 17914756446.99% | 3306.75% | -3630.90% | 3340.18% | -0.83 | 0.00 | 1.07 | -32.39 |
| KZIA | Kazia Therapeutics Limite… | $8.45 | 13.69M | +90% | -63% | — | +12,468% | -0.63 | -1.56 | 309.03 | -0.68 | — | -1.38 | 100.00% | -33850.00% | -49290.48% | 226.03% | 112.59% | -149.76% | -0.05 | — | 0.35 | 0.32 | 0.30 | -6564.00% | -9818.00% | 3859.00% | -102.30% | -0.94 | 114.02% | 0.00% | 0.00% | 22.54% | -0.64 | -0.68 | 215.01 | -40.14 |
| QLGN | Qualigen Therapeutics, In… | $3.21 | 5.43M | +38,771% | — | — | — | -0.18 | 0.42 | — | 0.01 | -0.03 | 0.42 | 0.00% | — | — | -2210.05% | -3863.24% | -189.27% | 0.00 | -6.34 | 2.33 | 1.59 | 0.22 | 60244.00% | -10000.00% | -3859.00% | -560.87% | -3.15 | -4242.60% | 7.77% | -1.40% | 191.43% | 0.01 | 0.01 | — | -39.80 |
| SILO | Silo Pharma, Inc. | $0.37 | 2.92M | +5,090% | +86% | — | — | -1.09 | 0.95 | 66.36 | 0.52 | — | 1.00 | 91.90% | -6526.44% | -6092.59% | -78.37% | 266.27% | -57.96% | 0.00 | -925.59 | 4.29 | 4.28 | 0.89 | -83.00% | 0.00% | 1890.00% | -80.13% | -2.32 | 216.94% | 0.00% | 0.00% | 11.59% | 0.49 | 0.60 | -31.84 | -2.88 |
| VYNE | VYNE Therapeutics Inc. | $0.60 | 10.01M | +3,912% | -43% | — | — | -0.98 | 0.93 | 45.39 | 0.12 | — | 0.93 | 0.00% | -4690.53% | -4646.14% | -66.33% | 505.69% | -54.57% | 0.00 | — | 12.53 | 12.11 | 0.90 | -3404.00% | 1377.00% | -283.00% | -128.02% | -13.83 | 626.52% | 0.00% | 0.00% | 16.23% | 0.12 | 0.09 | -5.50 | -30.50 |
| XBIO | Xenetic Biosciences, Inc. | $2.53 | 3.9M | +10,942% | -5% | — | — | -1.47 | 0.97 | 2.32 | 0.09 | — | 0.97 | 100.00% | -168.16% | -158.39% | -50.12% | -1285.35% | -45.24% | 0.00 | — | 7.37 | 6.89 | 1.52 | -517.00% | -156.00% | -3152.00% | -48.55% | -3.15 | -861.34% | 0.00% | 0.00% | 0.00% | 0.09 | 0.13 | -0.14 | -36.77 |
About Soligenix, Inc.
Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. It operates in two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of treat cutaneous T-cell lymphoma; and SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer. This segment also offers proprietary formulations of oral beclomethasone 17,21-dipropionate for the prevention/treatment of gastrointestinal disorders characterized by severe inflammation, including SGX203 for pediatric Crohn's disease; and SGX302 that is in Phase I/II clinical trial for the treatment of mild-to-moderate psoriasis. The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase Ia and Ib clinical trials; SGX943, a therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; and CiVax, a vaccine candidate in pre-clinical development for the prevention of COVID-19. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.
- CEO
- Christopher J. Schaber
- Employees
- 14
- Beta
- 2.01
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as (— ÷ $0.35) − 1 = — (DCF, example).